| Bioactivity | Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer[1][2]. |
| Invitro | Solitomab (1 μg/mL；4 小时) 对 EpCAM 阳性细胞株显示细胞毒性，并增加 EpCAM 阳性肉瘤 (CS) 细胞对 T 细胞细胞毒性的敏感性[1]。Solitomab (7 天) 增加 CD8+ 和 CD4+ T 细胞表面 CD25 和 HLA-DR 蛋白 (T 细胞激活标记物) 的表达水平[1]。Solitomab (0-2.5 μg/mL；4 小时) 对卵巢癌细胞有细胞毒作用，1 μg/mL 剂量对肿瘤杀伤效果最好[2]。 |
| Name | Solitomab |
| CAS | 1005198-65-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ferrari F, et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015 Oct 17;34:123. [2]. English DP, et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2015 Feb 1;121(3):403-12. |